


**FOURTH**  
**INFORMATION DISCLOSURE**  
**STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Application Number	10/531,594
Filing Date	November 28, 2005
First Named Inventor	Marc Blondel et al.
Examiner Name	Susan Marie Hanley
Attorney Docket No.	0070663-000002

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number-Kind Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Figures Appear
	US-			
	US-			
	US-			
	US-			
	US-			
	US-			
	US-			
	US-			
	US-			
	US-			
	US-			
	US-			
	US-			
	US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Foreign Patent Document	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant of Cited Document	STATUS							
	Country Code <sup>1</sup> , Number, Kind Code			Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec. / Pg. No(s).	

<sup>1</sup>Enter Office that issued the document, by the two-letter code.**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Deborah Tribouillard-Tanvier et al., "Antihypertensive Drug Guanabenz is Active <i>in vivo</i> Against Both Yeast and Mammalian Prions," (2008) PLoS ONE, 3(4):1-9, e1981
	Deborah Tribouillard-Tanvier et al., "Protein Folding Activity of Ribosomal RNA is a Selective Target of Two Unrelated Antiprion Drugs," PLoS ONE, 3(5):1-14, e2174
	Deborah Tribouillard-Tanvier et al., "Using Budding Yeast to Screen for Anti-Prion Drugs", (2006) Biotechnology Journal, 1:58-67
	Deborah Tribouillard-Tanvier et al., "Antiprion Drugs as Chemical Tools to uncover mechanisms of Prion Propagation," (2007) Prion 1:1, 48-52
	Stephane Bach et al., "Isolation of Drugs Active Against Mammalian Prions Using a Yeast-based Screening Assay," Nature Biotechnology (2003) 21(9):1075-1081

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.